FDA Issues New Warning for Gene Therapy Linked to Patient Deaths
The US Food and Drug Administration (FDA) has announced that it will be adding a new warning to a gene therapy for Duchenne’s muscular dystrophy, a fatal muscle-wasting disease that affects boys and young men. The infused therapy, called Elevidys, has been linked to two patient deaths and will now carry a boxed warning, the most serious type, alerting doctors and patients to the risk of potentially fatal liver failure.
Background and FDA Decision
The FDA’s decision comes after the company, Sarepta Therapeutics, reported the first of two deaths of teenage boys in March, followed by a second death reported in June. The FDA briefly called for halting all shipments of the drug but quickly reversed course after facing pushback from patient families and libertarian activists close to President Donald Trump. According to the FDA, the new warning and limitations are necessary to ensure the safe use of the therapy.
The one-time therapy, Elevidys, is the first US-approved gene therapy for Duchenne’s muscular dystrophy. In addition to the boxed warning, the FDA is also limiting the drug’s approved use to patients who are 4 years old and up and can still walk. Previously, the FDA had allowed the drug’s use in immobile patients, who generally have more advanced disease.
Precautionary Measures and Recommendations
New labeling will also recommend weekly liver function monitoring for the first three months of treatment, as well as other precautionary steps. These measures aim to minimize the risk of liver failure and ensure the safe use of the therapy. The FDA’s decision is based on data and expert opinions, and the agency will continue to monitor the safety and efficacy of the therapy.
Sarepta Therapeutics Inc. shares rose 7.7% in trading after the FDA announcement, reflecting improved visibility for investors about the company’s outlook. The company has faced significant challenges in recent months, including the layoff of 500 employees in July.
The FDA’s decision highlights the importance of careful evaluation and monitoring of new therapies, particularly those that carry significant risks. As the first US-approved gene therapy for Duchenne’s muscular dystrophy, Elevidys has the potential to improve the lives of patients with this devastating disease. However, it is crucial to ensure that the benefits of the therapy outweigh the risks, and that patients and doctors are aware of the potential risks involved.
For more information on this topic, visit Here
Image Source: www.twincities.com
